Crossmark

β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-025-01688-9

Published Online: 2025-02-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Bing

Xiao, Kang

Jia, Xiaoxi

Cao, Rundong

Liang, Donglin

A, Ruhan

Zhang, Weiwei

Li, Chunjie

Gao, Liping

Chen, Cao

Shi, Qi

Dong, Xiaoping
Funding

Funding for this research was provided by:

SKLID Development Grants from the National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, China CDC (2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503, 2021SKLID504, 2019SKLID401, 2019SKLID603, and 2021SKLID503)
License Information

Text and Data Mining valid from 2025-02-07

Version of Record valid from 2025-02-07
More Information

Article History

Received: 31 October 2024

Accepted: 30 January 2025

First Online: 7 February 2025

Declarations

:

: This study was approved by the Ethical Committee of the National Institute for Viral Disease Control and Prevention, China CDC, under protocol 2009ZX10004-101. All participants provided informed consent by the Declaration of Helsinki and local clinical research regulations.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below